Have a personal or library account? Click to login

Study of Decreased Susceptibility to Vancomycin in Methicillin-Resistant Staphylococcus aureus Strains isolated from a Romanian Multidisciplinary Emergency Hospital

Revista Romana de Medicina de Laborator
Volume 22 (2014): Issue 2 (June 2014)
By:
Open Access
|Jun 2014

References

  1. 1. van Hal SJ, Paterson DL. Systematic review and meta- analysis of the significance of heterogeneous vancomycin- intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55(1):405-10. DOI: 10.1128/AAC.01133-1010.1128/AAC.01133-10301965421078939
    Search in Google Scholar
  2. 2. Filleron A, Chironb R, Reverdyc ME, Jean-Pierred H, Dumitrescu O, et al. Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. Journal of Cystic Fibrosis 2011;10(5):377-82. DOI: 10.1016/j.jcf.2011.05.00110.1016/j.jcf.2011.05.00121636331
    Search in Google Scholar
  3. 3. Garnier F, Chainier D, Walsh T, Karlsson A, Bolmström A, Grelaud C, et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother. 2006;57(1):146-9. DOI: 10.1093/jac/dki41310.1093/jac/dki41316286482
    Search in Google Scholar
  4. 4. Charles PG, Ward PB, Johnson DR, Howden BP, Grayson LM. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448-51. DOI: 10.1086/38109310.1086/38109314727222
    Search in Google Scholar
  5. 5. Rong SL, Leonard SN. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother. 2010;44(5):844-50. DOI: 10.1345/ aph.1M52610.1345/aph.1M52620332341
    Search in Google Scholar
  6. 6. Wang Y, Hu YJ, Ai XM, Xu HT, Sun TY. Prevalence and clinical prognosis of heteroresistant vancomycin- intermediate Staphylococcus aureus in a tertiary care center in China. Chin Med J 2013;126(3):505-9.
    Search in Google Scholar
  7. 7. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Antimicrob Agents Chemoter. 2007;48:4926-8.
    Search in Google Scholar
  8. 8. EUCAST. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, Version 2.0. http://www. eucast.org/fileadmin/src/media/PDFs/EUCAST_files/ Breakpoint_tables/Breakpoint_table_v_2.0_120221. pdf.
    Search in Google Scholar
  9. 9. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. December 2012. http://www. eucast.org/fileadmin/src/media/PDFs/EUCAST_files/ Consultation/EUCAST_guidelines_detection_of_resistance_ mechanisms_121222.pdf.
    Search in Google Scholar
  10. 10. Székely E, Man A, Mare A, Vas KE, Molnár Sz, Bilca D, et al. Molecular epidemiology and virulence factors of methicillin-resistant Staphylococcus aureus strains in a Romanian university hospital. Rev Romana Med Lab. 2012;20(4):371-82.
    Search in Google Scholar
  11. 11. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile method to detect Staphylococcus aureus with decreased susceptibilities to vancomycin in a UK hospital. J Antimicrob Chemother. 2001;47(4):399-404. DOI: 10.1093/jac/47.4.39910.1093/jac/47.4.39911266410
    Search in Google Scholar
  12. 12. Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar Screening Methods. J Clin Microbiol. 2011;49(6):2147-50. DOI: 10.1128/ JCM.01435-1010.1128/JCM.01435-10312276221490190
    Search in Google Scholar
  13. 13. Shopsin B, Mathema B, Alcabes P, Said-Salim B, Lina G, Matsuka A, et al. Prevalence of agr specificity groups among Staphylococcus aureus strains colonizing children and their guardians. J Clin Microbiol. 2003;41(1):456-9. DOI: 10.1128/JCM.41.1.456-459.200310.1128/JCM.41.1.456-459.200314958312517893
    Search in Google Scholar
  14. 14. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate dtrains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99-139. DOI: 10.1128/CMR.00042-0910.1128/CMR.00042-09280665820065327
    Search in Google Scholar
  15. 15. Kirby A, Graham R, Williams NJ, Wootton M, Broughton CM, Alanazi M, et al. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother. 2010(4);65:721-4. DOI: 10.1093/jac/dkq00910.1093/jac/dkq00920124288
    Search in Google Scholar
  16. 16. Campanile F, Borbone S, Perez M, Bongiorno D, Cafiso V, Bertuccio T, et al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. International Journal of Antimicrobial Agents 2010;36(5):415-34. DOI: 10.1016/j. ijantimicag.2010.06.044
    Search in Google Scholar
  17. 17. Reverdy ME, Jarraud S, Bobin-Dubreux S, Burel E, Girado P, Lina G, et al. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clin Microbiol Inf. 2001;7(5):267-72. DOI: 10.1046/j.1198-743x.2001.00256.x10.1046/j.1198-743x.2001.00256.x11422254
    Search in Google Scholar
  18. 18. Nonhoff C, Denis O, Struelens MJ. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clinical Microbiology and Infection, 2005;11(3):214-20. DOI: 10.1111/j.1469-0691.2004.01060.x10.1111/j.1469-0691.2004.01060.x15715719
    Search in Google Scholar
  19. 19. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother. 2002;50(3):383-91. DOI: 10.1093/jac/dkf14210.1093/jac/dkf14212205063
    Search in Google Scholar
  20. 20. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sadar HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008;46(9):2950-4. DOI: 10.1128/JCM.00582-0810.1128/JCM.00582-08254672518632899
    Search in Google Scholar
  21. 21. Horne KC, Howden BP, Grabsch EA, Graham M, Ward PD, Xie S, et al. Prospective comparison of the clinical impact of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinsusceptible MRSA. Antimicrob Agents Chemother. 2009;53(8):3447-52. DOI: 10.1128/ AAC.01365-0810.1128/AAC.01365-08271562419506056
    Search in Google Scholar
  22. 22. Tóth A, Kispál G, Ungvári E, Violka M, Szeberin Z, Pászti J. First report of heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) causing fatal infection in Hungary. J Chemother. 2008;20(5):655-6. DOI: 10.1179/joc.2008.20.5.65510.1179/joc.2008.20.5.65519028632
    Search in Google Scholar
  23. 23. Dorneanu OS, Vremeră T, Năstase EV, Logigan C, Bădescu AC, Miftode EG. Detection of mecA gene in clinical Staphylococcus aureus isolates from Infectious Diseases Hospital, Iasi, Romania. Rev Romana Med Lab. 2011;19(3):259-65.
    Search in Google Scholar
  24. 24. Ionescu R, Mediavilla JR, Chen L, Grigorescu DO, Idomir M, Kreiswirth BN, et al. Molecular characterization and antibiotic susceptibility of Staphylococcus aureus from a multidisciplinary hospital in Romania. Microb Drug Resist. 2010;16(4):263-72. DOI: 10.1089/ mdr.2010.005910.1089/mdr.2010.005921034225
    Search in Google Scholar
  25. 25. Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin-tolerant and heterogeneous vancomycin- intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother. 2009;64(5):1024-8. DOI: 10.1093/jac/dkp31910.1093/jac/dkp31919744978
    Search in Google Scholar
  26. 26. Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA) in particular, heterogeneous GISA. J Clin Microbiol. 2008;46(9):3042-7. DOI: 10.1128/JCM.00265-0810.1128/JCM.00265-08254675418596146
    Search in Google Scholar
  27. 27. Filleron A, Chiron R, Reverdy ME, Jean-Pierre H, Du mitrescu O, Aleyrangues L, et al. Utility of the Etest GRD for detecting Staphylococcus aureus with reduced susceptibility to glycopeptides in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2012;31(4):599-604. DOI: 10.1007/s10096-011-1353-410.1007/s10096-011-1353-421904858
    Search in Google Scholar
  28. 28. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother. 2009;63(3):489-92. DOI: 10.1093/jac/dkn52010.1093/jac/dkn52019136530
    Search in Google Scholar
  29. 29. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39(7):2439-44. DOI: 10.1128/JCM.39.7.2439-2444.200110.1128/JCM.39.7.2439-2444.20018816711427551
    Search in Google Scholar
  30. 30. Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP. Underestimation of Vancomycin and Teicoplanin MICs by Broth Microdilution Leads to Underdetection of Glycopeptide-Intermediate Isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(9):3861-70. DOI: 10.1128/AAC.00269-1010.1128/AAC.00269-10293498120547791
    Search in Google Scholar
  31. 31. CDC. Algorithm for testing S. aureus with vancomycin. http://www.cdc.gov/HAI/settings/lab/visa_vrsa_algorithm. html. [Online]
    Search in Google Scholar
  32. 32. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 2007;45(2):329-32. DOI: 10.1128/JCM.01508-0610.1128/JCM.01508-06182900617108069
    Search in Google Scholar
  33. 33. Voss A, Mouton JW, van Elzakker EP, Hendrix RG, Goessens W, Kluytmans AJ, et al. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob. 2007;6:9. DOI: 10.1186/1476-0711-6-910.1186/1476-0711-6-9203458017892555
    Search in Google Scholar
  34. 34. ECDC. EARSS Manual 2005. http://www.ecdc.europa. eu/en/activities/surveillance/ears-net/documents/ ears-net-microbiological-manual.pdf. [Online]
    Search in Google Scholar
  35. 35. Fitzgibbon MM, Rossney AS, O’Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol. 2007;45(10):3263-9. DOI: 10.1128/JCM.00836-0710.1128/JCM.00836-07204535517687008
    Search in Google Scholar
  36. 36. Sakoulas G, Eliopoulos GM, Moellering RC Jr., Wennersten C, Venkataraman L, Novick RP, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 2002;46(5):1492-502. DOI: 10.1128/AAC.46.5.1492-1502.200210.1128/AAC.46.5.1492-1502.200212715311959587
    Search in Google Scholar
  37. 37. Sakoulas G, Eliopoulos GM, Moellering RC Jr., Novick RP, Venkataraman L, Wennersten C, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate- level glycopeptide resistance? J Infect Dis. 2003;187(6):929-38. DOI: 10.1086/36812810.1086/36812812660939
    Search in Google Scholar
  38. 38. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(3):1089-91. DOI: 10.1128/ AAC.00671-0610.1128/AAC.00671-06180312317158941
    Search in Google Scholar
  39. 39. Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother. 2013[Epub ahead of print]. DOI: 10.1128/AAC.00380-1310.1128/AAC.00380-13375432723796929
    Search in Google Scholar
  40. 40. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin- intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis. 2009;28(8):983-7. DOI: 10.1007/ s10096-009-0741-510.1007/s10096-009-0741-519387707
    Search in Google Scholar
  41. 41. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin- intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009;199(5):619-24. DOI: 10.1086/59662910.1086/59662919199552
    Search in Google Scholar
  42. 42. Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother. 2012;67(8):1843-9. DOI: 10.1093/jac/dks13110.1093/jac/dks13122535621
    Search in Google Scholar
  43. 43. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011;66(7):1594-9. DOI: 10.1093/jac/ dkr169
    Search in Google Scholar
  44. 44. Soriano A, Marco F, Martínez JA, Pisos E Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin- resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200. DOI: 10.1086/52466710.1086/52466718171250
    Search in Google Scholar
  45. 45. Sakoulas G, Moellering RC Jr., Eliopoulos GM. Ad aptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006;42(Suppl 1):40-50. DOI: 10.1086/49171310.1086/49171316323119
    Search in Google Scholar
  46. 46. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009;47(6):1640-4. DOI: 10.1128/JCM.02135-0810.1128/JCM.02135-08269107819369444
    Search in Google Scholar
DOI: https://doi.org/10.2478/rrlm-2014-0013 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 245 - 254
Submitted on: Dec 31, 2013
Accepted on: Apr 8, 2014
Published on: Jun 21, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
hVISA screening;glycopeptide resistance detection;population analysis
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2014 Krisztina Eszter Vas, Izabella Szász, Szabolcs Molnár, Lilla Lőrinczi, Edit Székely, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 22 (2014): Issue 2 (June 2014)Next article